At the heart of one of the largest European hospital complexes
Research programs and teams
Interdisciplinarity, transversality and diversification: LIRIC conducts its research activities in a way that promotes creativity and innovation.
Inflammatory digestive diseases: pathophysiology and the development of new therapeutic targets
The team led by Laurent Dubuquoy focuses on the pathophysiology of inflammatory digestive diseases. Its objective is to identify and propose new therapeutic targets for the treatment of inflammatory bowel diseases and alcoholic hepatitis.
Fungal-Associated Invasive and Inflammatory diseases
The research carried out by the team of Boulaem Sendid concerns the role of glycans in modulation of the inflammatory response and regulation of the adaptive response in two diseases linked to the opportunistic yeast Candida albicans: invasive candidosis and Crohn’s disease.
Immunity, Inflammation and Fibrosis in Auto- and Allo-Reactivity
Lennart MARS - Patrick VERMERSCH
Our research activities aim at understanding the pathophysiology of auto- and alloimmune inflammatory diseases and their complications, especially fibrosis. The team is composed of 2 groups : NEMESIS (multilple sclerosis and neuroinflammatory diseases), and FIRE (role of the immune system in fibrosis of inflammatory diseases, especially SSc and cGvHD)
Modulation of Infection and Inflammation through diet
Jean-Luc DESSEYN - Frédéric GOTTRAND
Our team studies the interactions between nutrition and epithelial inflammation, with particular emphasis on the mucus barrier, mainly in cystic fibrosis and IBDs. Our work is focused on the mechanisms of action and regulation of nutritional and environmental factors in inflammatory and infectious processes.
IBD and environmental factors: epidemiology and functional analyses
Our team’s work addresses a growing interest from the scientific community in the impact of environmental factors on inflammatory diseases, including IBDs.
Glycation: from inflammation to aging
Glycation is a major aging mechanism and a key factor in inflammatory processes.
Therapeutic Innovation Targeting Inflammation
Well upstream to the “drug discovery” process, our team’s scientific objective is the development of new chemical agents targeting inflammation and of new nanovectors improving the bioavailability of current and future treatments for the management of Inflammatory Bowel Diseases (IBD).
The LIRIC's Day
The LIRIC's day "News Entrants" was held on November 20th 2018 in the Institut Coeur-Poumon at CHU Lille.